Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1152 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Teplizumab for the delay of clinical type-1 diabetes in at-risk patients aged 8 years and over	Teplizumab (PRV-031; MGA031)	Type 1 diabetes	Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Tepotinib for advanced non-small cell lung cancer harbouring MET exon14- skipping mutations	Tepotinib (MSC-2156119J; TEPMETKO)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Teprotumumab for thyroid eye disease	Teprotumumab ((HZN-001; R-1507; RV 001)	Thyroid eye disease (TED)	Immunology	2024	View \| Download
Tezacaftor and ivacaftor for cystic fibrosis homozygous or heterozygous for F508del mutation in patients aged 12 years and older who discontinued treatment with Orkambi	Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one residual mutation in patients aged 6 to 11 years	Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 6 to 11 years	Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Tezepelumab for severe, uncontrolled asthma	Tezepelumab (AMG 157; MEDI9929)	Asthma	Respiratory System	2020	View \| Download
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps	Tezepelumab (AMG 157; MEDI9929)	Nasal polyps , Rhinosinusitis	Ear Nose and Throat (ENT)	2023	View \| Download
Ticagrelor for prevention of cardiovascular events in patients with type 2 diabetes mellitus who have coronary artery disease	Ticagrelor (Brilique; AZD6140)	Major cardiovascular events	Cardiovascular System	2018	View \| Download
Ticagrelor in addition to acetylsalicylic acid for prevention of stroke in patients with acute ischaemic stroke or transient ischaemic attack	Ticagrelor (Brilique; AZD6140)	Stroke	Cardiovascular System	2019	View \| Download